Assisted Reproductive Technology and IVF Segment Company in India Reports Rs 104.35 Crore Revenue in FY26, PAT Rises 28%

Gaudium IVF and Women Health Limited, one of India's leading fertility and women's healthcare platforms, reported strong financial performance for the fourth quarter and full financial year ended March 31, 2026, driven by higher patient volumes, robust clinical outcomes, and operational efficiencies.

The company reported revenue from operations of Rs 30.35 crore in Q4 FY26, compared to Rs 26.92 crore in the corresponding quarter last year, registering a growth of 12.74 per cent year-on-year (YoY). On a sequential basis, revenue increased 23.85 per cent from Rs 24.50 crore reported in Q3 FY26.

For the full financial year FY26, revenue from operations stood at Rs 104.35 crore, compared with Rs 70.72 crore in FY25, reflecting a strong 47.56 per cent YoY growth. The company attributed the growth to increasing patient volumes across mature centres and sustained clinical success rates.

Gaudium IVF's profitability improved significantly during the quarter. EBITDA for Q4 FY26 stood at Rs 12.17 crore, compared to Rs 8.72 crore in Q4 FY25, marking a growth of 39.56 per cent YoY. EBITDA margin expanded to 40.10 per cent, compared to 32.39 per cent in the year-ago quarter.

For FY26, EBITDA reached Rs 37.70 crore, up from Rs 28.63 crore in FY25, registering a 31.69 per cent increase. The EBITDA margin for the year stood at 36.13 per cent, supported by operating leverage and a greater contribution from advanced IVF treatment protocols.

Profitability at the bottom line also remained healthy. Profit After Tax (PAT) from continuing operations stood at Rs 8.36 crore in Q4 FY26, compared with Rs 6.45 crore in Q4 FY25, reflecting a 29.46 per cent YoY increase. PAT margin improved to 27.54 per cent during the quarter.

For the full year, PAT rose to Rs 24.48 crore, compared to Rs 19.17 crore in FY25, representing a growth of 27.69 per cent. PAT margin for FY26 stood at 23.47 per cent.

During FY26, the company operated a network of 7 hubs and 28 spokes across India and maintained a strong 58 per cent clinical pregnancy success rate on the first IVF attempt, reinforcing its position in the fertility care segment.

A key milestone during the year was the company's adoption of artificial intelligence-led embryology. In April 2026, Gaudium IVF became the first IVF chain in India to formally integrate AI-powered embryology into routine clinical practice through a partnership with U.K.-headquartered IVF 2.0. The company deployed the SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) platforms to improve embryo selection and treatment outcomes.

Commenting on the performance, Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF and Women Health Limited, said FY26 marked a transformational year for the company as it evolved into a listed and scalable fertility platform. She noted that IVF treatments remain the primary revenue driver, supported by the company's clinical success rates, while its pharmacy business continues to play a complementary role.

She further highlighted that the company's integrated healthcare model includes a 15-bed hospital facility in Janakpuri, enabling end-to-end patient care from fertility treatment through childbirth and post-natal services.

Looking ahead, Gaudium IVF plans to accelerate its expansion strategy using proceeds from its initial public offering (IPO). The company intends to establish 19 new IVF hubs, with three centres expected to become operational soon. It plans to expand to a total of 10 hubs in FY27, followed by eight additional hubs in FY28 and one hub in FY29, strengthening its presence in Tier-II cities while supporting metro centres with additional spokes.

Management believes that a debt-light balance sheet, a funded expansion roadmap, growing adoption of AI-driven fertility technologies, and the underpenetrated Indian fertility market provide a strong foundation for long-term growth.

Founded in 2009, Gaudium IVF and Women Health Limited offers a wide range of fertility and women's healthcare services, including IVF, ICSI, IUI, fertility preservation, advanced genetic testing, infertility treatment, high-risk pregnancy care, and minimally invasive gynecological procedures. The company currently operates centres across Delhi, Mumbai, Bengaluru, Patna, Ludhiana, and Srinagar.

Disclaimer: The article is for informational purposes only and not investment advice.